Total anticholinergic burden and risk of mortality and cardiovascular disease over 10 years in 21,636 middle-aged and older men and women of EPIC-Norfolk prospective population study

Phyo Kyaw Myint, Chris Fox, Chun Shing Kwok, Robert N Luben, Nicholas J Wareham, Kay-Tee Khaw

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

BACKGROUND: studies have raised concerns that medications with anticholinergic property have potential adverse effects on health outcomes.

OBJECTIVES: the objective of this study is to examine the prospective relationships between total anticholinergic burden (ACB) from medications and mortality, and cardiovascular disease (CVD) in a general population.

DESIGN: observational study.

SETTING: community cohort.

SUBJECTS: we examined data collected from 21,636 men and women without cancer at the baseline who participated in a baseline survey 1993-97 in the European Prospective Investigation into Cancer (EPIC)-Norfolk. They were followed until 2009/11.

METHODS: we performed Cox-proportional hazards models to determine the associations between total ACB and the subsequent risk of all-cause mortality and incident CVD during the follow-up.

RESULTS: there were a total of 4,342 people died and 7,328 had an incident CVD during the study follow-up (total person years = 322,321 years for mortality and 244,119 years for CVD event). Compared with people with no anticholinergic burden (ACB = 0), people with total ACB ≥3 from medications had hazards ratios of 1.83 (1.53, 2.20) and 2.17 (1.87, 2.52) for mortality and CVD incidence outcomes, respectively, after adjusting for potential confounders. Repeating the analyses after excluding people with prevalent illnesses, and events occurring within the first 2 years of follow-up, only slightly attenuated the results.

CONCLUSION: there appear to be a class effect as well as dose-response relationship between the ACB and both outcomes. Future research should focus on understanding the relationship between ACB and mortality, and cardiovascular disease and possibly minimising ACB load where feasible.

Original languageEnglish
Pages (from-to)219-225
Number of pages7
JournalAge and Ageing
Volume44
Issue number2
Early online date27 Nov 2014
DOIs
Publication statusPublished - Mar 2015

Fingerprint

Cholinergic Antagonists
Cardiovascular Diseases
Prospective Studies
Mortality
Population
Neoplasms
Proportional Hazards Models
Observational Studies
Incidence
Health

Keywords

  • anticholinergic burden
  • mortality
  • cardiovascular diseases
  • epidemiology
  • older people

Cite this

Total anticholinergic burden and risk of mortality and cardiovascular disease over 10 years in 21,636 middle-aged and older men and women of EPIC-Norfolk prospective population study. / Myint, Phyo Kyaw; Fox, Chris; Kwok, Chun Shing; Luben, Robert N; Wareham, Nicholas J; Khaw, Kay-Tee.

In: Age and Ageing, Vol. 44, No. 2, 03.2015, p. 219-225.

Research output: Contribution to journalArticle

@article{cc28a88ea49442698b2097c5c78bcbc1,
title = "Total anticholinergic burden and risk of mortality and cardiovascular disease over 10 years in 21,636 middle-aged and older men and women of EPIC-Norfolk prospective population study",
abstract = "BACKGROUND: studies have raised concerns that medications with anticholinergic property have potential adverse effects on health outcomes.OBJECTIVES: the objective of this study is to examine the prospective relationships between total anticholinergic burden (ACB) from medications and mortality, and cardiovascular disease (CVD) in a general population.DESIGN: observational study.SETTING: community cohort.SUBJECTS: we examined data collected from 21,636 men and women without cancer at the baseline who participated in a baseline survey 1993-97 in the European Prospective Investigation into Cancer (EPIC)-Norfolk. They were followed until 2009/11.METHODS: we performed Cox-proportional hazards models to determine the associations between total ACB and the subsequent risk of all-cause mortality and incident CVD during the follow-up.RESULTS: there were a total of 4,342 people died and 7,328 had an incident CVD during the study follow-up (total person years = 322,321 years for mortality and 244,119 years for CVD event). Compared with people with no anticholinergic burden (ACB = 0), people with total ACB ≥3 from medications had hazards ratios of 1.83 (1.53, 2.20) and 2.17 (1.87, 2.52) for mortality and CVD incidence outcomes, respectively, after adjusting for potential confounders. Repeating the analyses after excluding people with prevalent illnesses, and events occurring within the first 2 years of follow-up, only slightly attenuated the results.CONCLUSION: there appear to be a class effect as well as dose-response relationship between the ACB and both outcomes. Future research should focus on understanding the relationship between ACB and mortality, and cardiovascular disease and possibly minimising ACB load where feasible.",
keywords = "anticholinergic burden, mortality, cardiovascular diseases, epidemiology, older people",
author = "Myint, {Phyo Kyaw} and Chris Fox and Kwok, {Chun Shing} and Luben, {Robert N} and Wareham, {Nicholas J} and Kay-Tee Khaw",
note = "{\circledC} The Author 2014. Published by Oxford University Press on behalf of the British Geriatrics Society. All rights reserved. For Permissions, please email: journals.permissions@oup.com.",
year = "2015",
month = "3",
doi = "10.1093/ageing/afu185",
language = "English",
volume = "44",
pages = "219--225",
journal = "Age and Ageing",
issn = "0002-0729",
publisher = "OXFORD UNIV PRESS INC",
number = "2",

}

TY - JOUR

T1 - Total anticholinergic burden and risk of mortality and cardiovascular disease over 10 years in 21,636 middle-aged and older men and women of EPIC-Norfolk prospective population study

AU - Myint, Phyo Kyaw

AU - Fox, Chris

AU - Kwok, Chun Shing

AU - Luben, Robert N

AU - Wareham, Nicholas J

AU - Khaw, Kay-Tee

N1 - © The Author 2014. Published by Oxford University Press on behalf of the British Geriatrics Society. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

PY - 2015/3

Y1 - 2015/3

N2 - BACKGROUND: studies have raised concerns that medications with anticholinergic property have potential adverse effects on health outcomes.OBJECTIVES: the objective of this study is to examine the prospective relationships between total anticholinergic burden (ACB) from medications and mortality, and cardiovascular disease (CVD) in a general population.DESIGN: observational study.SETTING: community cohort.SUBJECTS: we examined data collected from 21,636 men and women without cancer at the baseline who participated in a baseline survey 1993-97 in the European Prospective Investigation into Cancer (EPIC)-Norfolk. They were followed until 2009/11.METHODS: we performed Cox-proportional hazards models to determine the associations between total ACB and the subsequent risk of all-cause mortality and incident CVD during the follow-up.RESULTS: there were a total of 4,342 people died and 7,328 had an incident CVD during the study follow-up (total person years = 322,321 years for mortality and 244,119 years for CVD event). Compared with people with no anticholinergic burden (ACB = 0), people with total ACB ≥3 from medications had hazards ratios of 1.83 (1.53, 2.20) and 2.17 (1.87, 2.52) for mortality and CVD incidence outcomes, respectively, after adjusting for potential confounders. Repeating the analyses after excluding people with prevalent illnesses, and events occurring within the first 2 years of follow-up, only slightly attenuated the results.CONCLUSION: there appear to be a class effect as well as dose-response relationship between the ACB and both outcomes. Future research should focus on understanding the relationship between ACB and mortality, and cardiovascular disease and possibly minimising ACB load where feasible.

AB - BACKGROUND: studies have raised concerns that medications with anticholinergic property have potential adverse effects on health outcomes.OBJECTIVES: the objective of this study is to examine the prospective relationships between total anticholinergic burden (ACB) from medications and mortality, and cardiovascular disease (CVD) in a general population.DESIGN: observational study.SETTING: community cohort.SUBJECTS: we examined data collected from 21,636 men and women without cancer at the baseline who participated in a baseline survey 1993-97 in the European Prospective Investigation into Cancer (EPIC)-Norfolk. They were followed until 2009/11.METHODS: we performed Cox-proportional hazards models to determine the associations between total ACB and the subsequent risk of all-cause mortality and incident CVD during the follow-up.RESULTS: there were a total of 4,342 people died and 7,328 had an incident CVD during the study follow-up (total person years = 322,321 years for mortality and 244,119 years for CVD event). Compared with people with no anticholinergic burden (ACB = 0), people with total ACB ≥3 from medications had hazards ratios of 1.83 (1.53, 2.20) and 2.17 (1.87, 2.52) for mortality and CVD incidence outcomes, respectively, after adjusting for potential confounders. Repeating the analyses after excluding people with prevalent illnesses, and events occurring within the first 2 years of follow-up, only slightly attenuated the results.CONCLUSION: there appear to be a class effect as well as dose-response relationship between the ACB and both outcomes. Future research should focus on understanding the relationship between ACB and mortality, and cardiovascular disease and possibly minimising ACB load where feasible.

KW - anticholinergic burden

KW - mortality

KW - cardiovascular diseases

KW - epidemiology

KW - older people

U2 - 10.1093/ageing/afu185

DO - 10.1093/ageing/afu185

M3 - Article

C2 - 25430550

VL - 44

SP - 219

EP - 225

JO - Age and Ageing

JF - Age and Ageing

SN - 0002-0729

IS - 2

ER -